Alimera Sciences, Inc. (NASDAQ:ALIM) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Monday.
Several other equities research analysts have also recently issued reports on ALIM. Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Tuesday, July 11th. Finally, Cowen and Company reissued a “buy” rating and set a $3.00 price target on shares of Alimera Sciences in a research report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Alimera Sciences currently has an average rating of “Hold” and an average price target of $3.38.
Shares of Alimera Sciences (NASDAQ:ALIM) traded up 2.22% during midday trading on Monday, hitting $1.38. 104,554 shares of the stock traded hands. The stock’s market cap is $95.29 million. Alimera Sciences has a 12-month low of $1.03 and a 12-month high of $1.72. The company’s 50 day moving average price is $1.43 and its 200-day moving average price is $1.43.
Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million for the quarter, compared to analyst estimates of $10.20 million. During the same period last year, the firm earned ($0.17) EPS. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities research analysts expect that Alimera Sciences will post ($0.21) EPS for the current year.
Several hedge funds have recently made changes to their positions in ALIM. KCG Holdings Inc. boosted its position in shares of Alimera Sciences by 127.0% during the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 43,977 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Alimera Sciences by 24.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 35,200 shares during the last quarter. Kennedy Capital Management Inc. acquired a new position in shares of Alimera Sciences during the 1st quarter valued at about $467,000. Finally, JW Asset Management LLC boosted its position in shares of Alimera Sciences by 15.6% during the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after acquiring an additional 130,000 shares during the last quarter. 37.20% of the stock is currently owned by hedge funds and other institutional investors.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.